What is Chimeric Therapeutics?
Founded in 2020, Chimeric Therapeutics operates at the intersection of advanced biotechnology and clinical oncology. The company is dedicated to the discovery and development of novel therapeutic modalities designed to improve patient outcomes in complex cancer cases. By maintaining a robust portfolio of research-driven assets, the firm bridges the gap between laboratory innovation and practical medical application. Its operational model relies on strategic collaborations with leading healthcare institutions, ensuring that its development pipeline remains aligned with current clinical standards and unmet medical needs. As a key player in the Australian biotech sector, Chimeric Therapeutics utilizes its research infrastructure to navigate the high-stakes environment of drug development, focusing on long-term value creation through scientific excellence.
How much funding has Chimeric Therapeutics raised?
Chimeric Therapeutics has raised a total of $53.5M across 3 funding rounds:
Stock Offering
$35M
Share Placement
$10.1M
Stock/Share Issuance
$8.4M
Stock Issuance/Offering (2021): $35M, investors not publicly disclosed
Share Placement (2023): $10.1M, investors not publicly disclosed
Stock/Share Issuance (2025): $8.4M, investors not publicly disclosed
Key Investors in Chimeric Therapeutics
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Chimeric Therapeutics?
With the recent influx of capital, Chimeric Therapeutics is well-positioned to scale its clinical trial operations and expand its research capabilities. The strategic deployment of these funds will likely prioritize the advancement of its lead candidates through critical regulatory milestones, enhancing the company's intellectual property portfolio. As the firm transitions into a more mature phase of its lifecycle, the focus will shift toward optimizing its development roadmap and potentially exploring new partnerships to broaden its therapeutic reach. Investors and stakeholders will be monitoring the company's ability to translate this financial momentum into tangible clinical data, which remains the primary driver of valuation in the biotechnology sector. The company's ability to maintain its research velocity while managing the complexities of late-stage clinical development will be the defining factor in its future market performance.
See full Chimeric Therapeutics company page
